Edition:
United Kingdom

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

2.85USD
17 Aug 2018
Change (% chg)

$-0.10 (-3.39%)
Prev Close
$2.95
Open
$2.94
Day's High
$2.94
Day's Low
$2.85
Volume
179,475
Avg. Vol
144,974
52-wk High
$7.98
52-wk Low
$2.06

Latest Key Developments (Source: Significant Developments)

Tetraphase Pharmaceuticals Q2 Loss Per Share $0.18
Thursday, 2 Aug 2018 

Tetraphase Pharmaceuticals Inc ::TETRAPHASE PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q2 LOSS PER SHARE $0.18.Q2 REVENUE $11.6 MILLION VERSUS $1.6 MILLION.Q2 REVENUE VIEW $2.2 MILLION -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S.  Full Article

Tetraphase Pharmaceuticals Announces Submission Of NDA To FDA For Eravacycline To Treat Intra-Abdominal Infections
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Tetraphase Pharmaceuticals Inc ::TETRAPHASE PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO FDA FOR ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI).TETRAPHASE PHARMACEUTICALS INC - NDA SUBMISSION INCLUDES DATA FROM IGNITE1 AND IGNITE 4 PHASE 3 CLINICAL TRIALS.  Full Article

Millennium Management Llc Reports 5.3 Pct Passive Stake In Tetraphase Pharmaceuticals As On Dec 14
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Millennium Management Llc::MILLENNIUM MANAGEMENT LLC REPORTS 5.3 PERCENT PASSIVE STAKE IN TETRAPHASE PHARMACEUTICALS AS ON DEC 14 - SEC FILING.  Full Article

Tetraphase Pharmaceuticals Q3 loss per share $0.63
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Tetraphase Pharmaceuticals Inc :Tetraphase pharmaceuticals reports third quarter 2017 financial results and highlights recent clinical and corporate achievements.Q3 loss per share $0.63.Q3 revenue $4.1 million versus $900,000.Q3 revenue view $1.3 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.69 -- Thomson Reuters I/B/E/S.  Full Article

Tetraphase Pharmaceuticals signs commercial supply agreement with Finorga
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Tetraphase Pharmaceuticals Inc ::Tetraphase Pharmaceuticals Inc says ‍on October 16 co and finorga sas entered into a commercial supply agreement​ - sec filing.Tetraphase Pharmaceuticals - ‍under supply agreement finorga sas will make for commercial supply active pharmaceutical ingredient for eravacycline for co​.Tetraphase Pharmaceuticals- ‍supply agreement has initial term ending Oct 16, 2022.  Full Article

TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CFO
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Tetraphase Pharmaceuticals Inc ::TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CHIEF FINANCIAL OFFICER.‍MOST RECENTLY, KAMALAM UNNINAYAR​ SPENT OVER 11 YEARS OVERSEEING FINANCE ORGANIZATIONS AT THERMO FISHER SCIENTIFIC.KAMALAM UNNINAYAR MOST RECENTLY SPENT OVER 11 YEARS OVERSEEING FINANCE ORGANIZATIONS AT THERMO FISHER SCIENTIFIC​.  Full Article

Tetraphase pharmaceuticals doses first patient in IGNITE4 phase 3 clinical trial of Eravacycline in cIAI
Friday, 14 Oct 2016 

Tetraphase Pharmaceuticals Inc : Tetraphase Pharmaceuticals doses first patient in IGNITE4 phase 3 clinical trial of eravacycline in cIAI . Tetraphase Pharmaceuticals Inc - top-line IGNITE4 data expected in 4Q 2017 .Tetraphase Pharmaceuticals Inc- study is expected to enroll approximately 450 adult patients.  Full Article

BRIEF-Tetraphase Pharmaceuticals Elects Christopher Watt As Principal Financial Officer

* TETRAPHASE PHARMACEUTICALS - BOARD ELECTED CHRISTOPHER WATT AS PRINCIPAL FINANCIAL OFFICER & PRINCIPAL ACCOUNTING OFFICER UNTIL CFO IS NAMED